Trial Profile
A phase 3, 12-month, extension study to evaluate the safety of asoprisnil in subjects with uterine leiomyomata
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Asoprisnil (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Sponsors TAP Pharmaceutical Products
- 27 Oct 2006 New trial record.